{"id":611355,"date":"2022-08-09T18:32:01","date_gmt":"2022-08-09T18:32:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=611355"},"modified":"2022-08-09T18:32:01","modified_gmt":"2022-08-09T18:32:01","slug":"sialorrhea-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-merz-pharma-proveca-neurohealing-neos-pharma-orient-pharma-us-worldmeds","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sialorrhea-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2032-delveinsight-key-companies-merz-pharma-proveca-neurohealing-neos-pharma-orient-pharma-us-worldmeds_611355.html","title":{"rendered":"Sialorrhea Market is Projected to Boost at a Moderate Growth Rate by 2032 – DelveInsight | Key Companies – Merz Pharma, Proveca, NeuroHealing, Neos Pharma, Orient Pharma, US WorldMeds"},"content":{"rendered":"
\n
\"Sialorrhea<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
According to DelveInsight, the Sialorrhea therapeutic market size in the seven major markets was USD 1073.62 Million in 2017 and is expected to increase during the forecast period (2032). Among the 7MM, the United States accounts for the largest market size for Sialorrhea in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.<\/div>\n

DelveInsight’s “Sialorrhea Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Sialorrhea Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Sialorrhea market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"\"<\/p>\n

Sialorrhea: An Overview<\/strong><\/p>\n

Sialorrhea, also known as ptyalis, is the condition of excessive drooling in children with cerebral palsy and adults who suffers from neurodegenerative disorders. Drooling is of two types, anterior and posterior drooling. Anterior drooling is defined as saliva spilled from the mouth that is clearly visible. When saliva spills through the oropharynx and into the hypopharynx, it is known as posterior drooling.<\/p>\n

Drooling saliva is normal in infants but usually stops by 15 to 18 months of age. Past the age of 4 years, it is usually considered to be pathologic. Pathologic sialorrhea is a common problem in neurologically impaired children (i.e., those with mental retardation or cerebral palsy) and adults with Parkinson’s disease or a stroke.<\/em><\/p>\n

Sialorrhea Market Key Facts<\/strong><\/p>\n